Vascular Biogenics Ltd buy marge
Zusammenfassung
Diese Einschätzung wurde am 20.12.18 mit einem Endkurs von 0,97 € beendet. Herbe Verluste von -80,55 % verzeichnete die BUY Einschätzung von marge. marge hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Vascular Biogenics Ltd | - | - | - | - |
| iShares Core DAX® | 1,08 % | -0,85 % | 12,46 % | 58,47 % |
| iShares Nasdaq 100 | -1,67 % | -3,31 % | 1,50 % | 84,47 % |
| iShares Nikkei 225® | 3,86 % | 6,31 % | 22,27 % | 56,19 % |
| iShares S&P 500 | 0,11 % | -1,34 % | 1,10 % | 58,32 % |
Kommentare von marge zu dieser Einschätzung
In der Diskussion Vascular Biogenics Ltd diskutieren
Vascular is well funded and is targeting potential lucrative markets.
The company's lead oncology product candidate is VB-111 for solid tumor indications. Vascular's lead compound VB-111 is the first highly targeted anti-angiogenic agent for the specific inhibition of tumor
vascular growth to use the vascular targeting system. VB-111 is administered via an IV. The firm has obtained fast track designation for VB-111 in the United States for prolongation of survival in patients
with glioblastoma that has recurred following a treatment with standard chemotherapy and radiation. Furthermore, the company has also received orphan drug designation in both the United States and Europe. VB-11's most advanced indication is in recurrent glioblastoma, which is currently in a pivotal phase 3 trial. Interim analysis, for the phase 3 GLOBE trial, is expected to occur in mid-2017.
Vascular remains a high-risk investment stock, but has a favorable risk/reward profile and is worthy of a small position within a well-diversified biotech portfolio.